A SARS‐CoV and SARS‐CoV‐2 RBD Heterodimer Vaccine Candidate
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Rong Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Sciences and Veterinary Medicine, Guangxi University (GXU), Nanning, China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, Spike Glycoprotein, Coronavirus, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: This study was supported by the National Key Research and Development Program of China (2020YFA0509202, 2020YFA0907102, and 2023YFC2307801), the Youth Team Pro….
Abstract (Originalsprache)
The continuous evolution of SARS‐CoV‐2 through accumulating mutations, combined with the persistent risk of zoonotic sarbecovirus transmission events, highlights the critical demand for broadly protective vaccines. Building on our previous findings that a heterodimeric receptor‐binding domain (RBD) design substantially improves cross‐reactive immunogenicity in vaccine candidates, we propose this strategy as a foundation for developing pan‐sarbecovirus vaccines with cross‐neutralizing capacity against diverse and emerging variants. In this study, we developed a sarbecovirus immunogen, utilizing a heterodimeric strategy incorporating the RBDs from both SARS‐CoV and SARS‐CoV‐2. Pseudovirus neutralization assays revealed that mice immunized with the SARS‐CoV‐2 prototype (PT)‐SARS‐CoV heterodimer (PT‐SARS) developed 39.9‐ to 305.6‐fold higher neutralizing antibody (NAb) titers against SARS‐CoV‐2 sub‐variants compared to the SARS‐CoV RBD homodimer (SARS‐SARS). Furthermore, PT‐SARS elicited 17.6‐ and 31.2‐fold enhanced neutralization against WIV1 and SARS‐CoV, respectively, relative to the SARS‐CoV‐2 PT homodimer (PT‐PT). To address evolving Omicron sub‐variants, we further updated BA.1‐SARS and BA.2‐SARS immunogens. Notably, BA.2‐SARS exhibited a 6.2‐fold increase in neutralizing potency against BA.2.86 compared to PT‐SARS. Crucially, the heterodimeric immunogen induced balanced and broadly reactive NAbs against multiple sarbecoviruses, including RaTG13, Pangolin GD, SARS‐CoV, and SARS‐CoV‐2 variants/sub‐variants, demonstrating its potential as a sarbecovirus immunogen candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Animal Sciences and Veterinary Medicine, Guangxi University (GXU), Nanning, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Chinese Academy of Sciences (CAS), Beijing, China.
- School of Life Science, University of Science and Technology of China (USTC), Hefei, China.
- Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, China.
- Beijing Life Science Academy, Beijing, China.
ORCID-Profile: George F Gao
Förderung
- This study was supported by the National Key Research and Development Program of China (2020YFA0509202, 2020YFA0907102, and 2023YFC2307801), the Youth Team Pro…
Zitieren
APA
Zhang, R., Li, D., Gao, P., Ruan, W., Qiao, S., Xu, S., Dai, L., Luo, T., Zhao, X., & Gao, G. F. (2025). A SARS‐CoV and SARS‐CoV‐2 RBD Heterodimer Vaccine Candidate. Journal of Medical Virology. https://doi.org/10.1002/jmv.70367
Vancouver
Zhang R, Li D, Gao P, Ruan W, Qiao S, Xu S, et al. A SARS‐CoV and SARS‐CoV‐2 RBD Heterodimer Vaccine Candidate. Journal of Medical Virology. 2025. doi:10.1002/jmv.70367
BibTeX
@article{Zhang2025,
author = {Zhang, Rong and Li, Dedong and Gao, Pengyue and Ruan, Wenjing and Qiao, Shitong and Xu, Senyu and Dai, Lianpan and Luo, Tingrong and Zhao, Xin and Gao, George F},
title = {A SARS‐CoV and SARS‐CoV‐2 RBD Heterodimer Vaccine Candidate},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70367}
}
EUVIMED